Your browser doesn't support javascript.
loading
Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial.
Galgani, Ilaria; Põder, Airi; Jõgi, Rain; Anttila, Veli-Jukka; Milleri, Stefano; Borobia, Alberto M; Launay, Odile; Testa, Marco; Casula, Daniela; Grassano, Luca; Tasciotti, Annaelisa; Dozot, Marie; Arora, Ashwani K.
Affiliation
  • Galgani I; GSK, Siena, Italy.
  • Põder A; The Clinical Research Center, Tartu, Estonia.
  • Jõgi R; The Lung Clinic, Tartu University Hospital, Tartu, Estonia.
  • Anttila VJ; Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland.
  • Milleri S; Centro Ricerche Cliniche di Verona Srl, Verona, Italy.
  • Borobia AM; Clinical Pharmacology Department, La Paz University Hospital, IdiPAZ, Madrid, Spain.
  • Launay O; School of Medicine, Autonomous University of Madrid, Madrid, Spain.
  • Testa M; Spanish Clinical Research Network - SCReN, Madrid, Spain.
  • Casula D; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Grassano L; Université Paris Cité, Paris, France.
  • Tasciotti A; Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France.
  • Dozot M; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.
  • Arora AK; GSK, Siena, Italy.
Hum Vaccin Immunother ; 19(1): 2187194, 2023 12 31.
Article in En | MEDLINE | ID: mdl-36974988
ABSTRACT
A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines containing the same AS01-adjuvant system could lead to immune interference. We compared administration of NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. This phase 2a, open-label trial (NCT03894969) randomized healthy current or former smokers (50-80 years) without COPD to administration of NTHi-Mcat at 1, 3 or 6 months after RZV or to NTHi-Mcat alone (2-dose for both vaccines). Primary outcome was non-inferiority of the humoral immune response to NTHi-Mcat administered 1 month after RZV versus NTHi-Mcat alone, evaluated by specific antibody geometric mean concentration (GMC) ratio with 95% confidence intervals (CIs). The per-protocol set included 411 participants. Primary objective was met; lower limit of the 95%CI for the GMC ratio above 0.667 for all four vaccine antigens, 1 month after the second NTHi-Mcat dose. NTHi-Mcat induced similar immune response regardless of whether administered alone or 1, 3 or 6 months following RZV. Safety and reactogenicity profiles were acceptable; adverse event frequency was similar among study groups. Injection site pain was the most common symptom. No new safety concerns were identified. The study demonstrated non-inferiority of the immune response elicited by NTHi-Mcat administered sequentially to RZV versus NTHi-Mcat alone, indicating no immune interference. Starting from 1 month, no specific interval is required between RZV and NTHi-Mcat containing the same AS01-adjuvant system components in different quantities.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / Herpes Zoster Vaccine / Herpes Zoster Type of study: Clinical_trials Limits: Humans Language: En Journal: Hum Vaccin Immunother Year: 2023 Type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / Herpes Zoster Vaccine / Herpes Zoster Type of study: Clinical_trials Limits: Humans Language: En Journal: Hum Vaccin Immunother Year: 2023 Type: Article Affiliation country: Italy